BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17111207)

  • 1. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.
    Rugo H; Shtivelman E; Perez A; Vogel C; Franco S; Tan Chiu E; Melisko M; Tagliaferri M; Cohen I; Shoemaker M; Tran Z; Tripathy D
    Breast Cancer Res Treat; 2007 Sep; 105(1):17-28. PubMed ID: 17111207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer.
    Perez AT; Arun B; Tripathy D; Tagliaferri MA; Shaw HS; Kimmick GG; Cohen I; Shtivelman E; Caygill KA; Grady D; Schactman M; Shapiro CL
    Breast Cancer Res Treat; 2010 Feb; 120(1):111-8. PubMed ID: 20054647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2 study of perifosine in advanced or metastatic breast cancer.
    Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ
    Breast Cancer Res Treat; 2008 Mar; 108(1):87-92. PubMed ID: 17458693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
    Smith JW; McIntyre KJ; Acevedo PV; Encarnacion CA; Tedesco KL; Wang Y; Asmar L; O'Shaughnessy JA
    Breast Cancer Res Treat; 2009 Nov; 118(2):361-7. PubMed ID: 19459042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
    Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
    Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells.
    Fong S; Shoemaker M; Cadaoas J; Lo A; Liao W; Tagliaferri M; Cohen I; Shtivelman E
    Cancer Biol Ther; 2008 Apr; 7(4):577-86. PubMed ID: 18305410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital.
    Lu CH; Lin YC; Chang HK
    Chang Gung Med J; 2007; 30(1):33-40. PubMed ID: 17477027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
    Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
    Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study.
    Eichbaum MH; Schuetz F; Khbeis T; Lauschner I; Foerster F; Sohn C; Schneeweiss A
    Anticancer Drugs; 2007 Sep; 18(8):963-8. PubMed ID: 17667603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.
    Blakely LJ; Buzdar A; Chang HY; Frye D; Theriault R; Valero V; Rivera E; Booser D; Kuritani J; Tsuda M
    Clin Cancer Res; 2004 Aug; 10(16):5425-31. PubMed ID: 15328180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
    Gomez HL; Doval DC; Chavez MA; Ang PC; Aziz Z; Nag S; Ng C; Franco SX; Chow LW; Arbushites MC; Casey MA; Berger MS; Stein SH; Sledge GW
    J Clin Oncol; 2008 Jun; 26(18):2999-3005. PubMed ID: 18458039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
    Garin A; Manikhas A; Biakhov M; Chezhin M; Ivanchenko T; Krejcy K; Karaseva V; Tjulandin S
    Breast Cancer Res Treat; 2008 Jul; 110(2):309-15. PubMed ID: 17851759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
    J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of S-1 in pretreated metastatic breast cancer patients.
    Shien T; Shimizu C; Akashi-Tanaka S; Yonemori K; Kohno T; Hojo T; Ando M; Katsumata N; Kinoshita T; Fujiwara Y
    Jpn J Clin Oncol; 2008 Mar; 38(3):172-5. PubMed ID: 18296424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
    Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
    J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.